Allopurinol NDC 63187-463

NDC codes

FDA NDC Directory

Product NDC (as listed)63187-463Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63187-0463Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
63187-463-30	63187046330	30 TABLET in 1 BOTTLE, PLASTIC (63187-463-30)Marketed from Dec 1, 2018
63187-463-60	63187046360	60 TABLET in 1 BOTTLE, PLASTIC (63187-463-60)Marketed from Feb 22, 2023
63187-463-90	63187046390	90 TABLET in 1 BOTTLE, PLASTIC (63187-463-90)Marketed from Feb 22, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Allopurinol
Generic name (nonproprietary): allopurinol
Active ingredients: Allopurinol — 100 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Proficient Rx LP
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 018832
Marketing start: Apr 6, 2009
Listing expires: Dec 31, 2026
Other FDA classes: Xanthine Oxidase Inhibitors (Mechanism)
Identifiers: Product ID 63187-463_dc8eb4a8-0fb0-4964-9d48-b299f99744f6SPL ID dc8eb4a8-0fb0-4964-9d48-b299f99744f6SPL set ID 0ca4baed-c5d8-4de4-ac17-6e5d1df15c03RxCUI 197319, 197320UNII 63CZ7GJN5IUPC 0363187463304, 0363187240301
Pharmacologic class: Xanthine Oxidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N463187046330 followed by a unit qualifier and the quantity

Package 63187-0463-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 1, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS and PRECAUTIONS ). Allopurinol is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes eleva…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 018832

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 018832
Product	Strength	Form · route	Labeler	Product NDC
Allopurinol	Allopurinol 100 mg/1	TabletOral	Actavis Pharma, Inc.	0591-5543